Endometrial cancer is one of the most common cancer of the female reproductive tract, which has been one of the primary causes of cancer related deaths and accounts for approximately ¼ of these patients. In this paper, HEC-1 cell l i n e s that are known to propagate endometrial cancer have been considered as potential sites of action for various therapeutic agents in an attempt to combat proliferation. Ancient Chinese remedies are by far the most recognized therapeutic method which have been found to relieve patients suffering from a tumor and also suppresses tumor growth. This study researches the effect of an injection formulation of the compound Kushen, which is a large oxysophocarpine-associated compound. In CKI- handled tumor cells, cellular proliferation through DNA synthesis and mobile differentiation seems to be a surprisingly modified mechanism. Cell cycle inhibition is seen to be one of the key mechanisms in CKI mediated tumor suppression in most instances. This is based on the fact that aggregates display certain 2-D specifications and dimerization of genes within the proposed mechanisms [10]. There is, nevertheless, little to no proof that oxysophocarpine, specifically in endometrial cells HEC-1B, inhibits the growth of most cancers’ cells.
| Published in | Journal of Gynecology and Obstetrics (Volume 10, Issue 2) |
| DOI | 10.11648/j.jgo.20221002.17 |
| Page(s) | 97-107 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Cancer, Tumor, Proliferation, HEC-1B Cells, Oxysophocarpine, Kushen, Anti-tumor
| [1] | AHILL, H., WILLIAMELEY, J., CHARLAN, L., SGREENBERG, R., JBARRETTII, R. and WCHEN, V. (1996). Racial differences in endometrial cancer survival: The black/white cancer survival study. Obstetrics & Gynecology, 88 (6), pp. 919–926. |
| [2] | Amant, F., Moerman, P., Neven, P., Timmerman, D., Van Limbergen, E. and Vergote, I. (2005). Endometrial cancer. The Lancet, [online] 366 (9484), pp. 491–505. Available at: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67063-8/references [Accessed 2 Mar. 2021]. |
| [3] | Anzai, Y., Gong, Y., Holinka, C. F., Murphy, L. J., Murphy, L. C., Kuramoto, H. and Gurpide, E. (1992). Effects of transforming growth factors and regulation of their mRNA levels in two human endometrial adenocarcinoma cell lines. The Journal of Steroid Biochemistry and Molecular Biology, [online] 42 (5), pp. 449–455. Available at: https://www.sciencedirect.com/science/article/pii/096007609290256I# [Accessed 4 Mar. 2021]. |
| [4] | Barrena Medel, N. I., Bansal, S., Miller, D. S., Wright, J. D. and Herzog, T. J. (2009). Pharmacotherapy of endometrial cancer. Expert Opinion on Pharmacotherapy, 10 (12), pp. 1939–1951. |
| [5] | Browder, T., Butterfield, C. E., Kräling, B. M., Shi, B., Marshall, B., O’Reilly, M. S. and Folkman, J. (2000). Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Research, [online] 60 (7), pp. 1878–1886. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10766175 [Accessed 5 Mar. 2021]. |
| [6] | Calle, E. E. and Kaaks, R. (2004). Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nature Reviews Cancer, 4 (8), pp. 579–591. |
| [7] | Carmeliet, P. (2005). VEGF as a Key Mediator of Angiogenesis in Cancer. Oncology, 69 (3), pp. 4–10. |
| [8] | Chen, H., Zhang, J., Luo, J., Lai, F., Wang, Z., Tong, H., Lu, D., Bu, H., Zhang, R. and Lin, S. (2013a). Antiangiogenic effects of oxymatrine on pancreatic cancer by inhibition of the NF-κB-mediated VEGF signaling pathway. Oncology Reports, [online] 30 (2), pp. 589–595. Available at: https://pubmed.ncbi.nlm.nih.gov/23754270/ [Accessed 5 Mar. 2021]. |
| [9] | Chen, K., Zhang, S., Ji, Y., Li, J., An, P., Ren, H., Liang, R., Yang, J. and Li, Z. (2013b). Baicalein Inhibits the Invasion and Metastatic Capabilities of Hepatocellular Carcinoma Cells via Down-Regulation of the ERK Pathway. PLoS ONE, 8 (9), p. e72927. |
| [10] | Cui, J., Qu, Z., Harata-Lee, Y., Shen, H., Aung, T. N., Wang, W., Kortschak, R. D. and Adelson, D. L. (2020). The effect of compound kushen injection on cancer cells: Integrated identification of candidate molecular mechanisms. PLOS ONE, 15 (7), p. e0236395. |
| [11] | Dai, Z., Gao, J., Wu, W., Wang, X., Li, Z., Kang, H., Liu, X. and Ma, X. (2007). [Effect of matrine injections on invasion and metastasis of gastric carcinoma SGC-7901 cells in vitro]. Zhong Yao Cai = Zhongyaocai = Journal of Chinese Medicinal Materials, [online] 30 (7), pp. 815–819. Available at: https://pubmed.ncbi.nlm.nih.gov/17944193/ [Accessed 8 Mar. 2021]. |
| [12] | Dai, Z.-J., Gao, J., Wang, X.-J., Ji, Z.-Z., Wu, W.-Y., Liu, X.-X., Kang, H.-F., Guan, H.-T. and Ren, H.-T. (2008). [Apoptotic mechanism of gastric carcinoma cells induced by matrine injection]. Zhonghua Wei Chang Wai Ke Za Zhi = Chinese Journal of Gastrointestinal Surgery, [online] 11 (3), pp. 261–265. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18478473 [Accessed 8 Mar. 2021]. |
| [13] | Escobedo, L. G., Lee, N. C., Peterson, H. B. and Wingo, P. A. (1991). Infertility-associated endometrial cancer risk may be limited to specific subgroups of infertile women. Obstetrics and Gynecology, [online] 77 (1), pp. 124–128. Available at: https://www.ncbi.nlm.nih.gov/pubmed/1984211 [Accessed 2 Mar. 2021]. |
| [14] | Europe PMC (2016). Europe PMC. [online] Europepmc.org. Available at: https://europepmc.org/article/med/26015570 [Accessed 5 Mar. 2021]. |
| [15] | Eycken E, V. (2000). Seminar. [online]. Available at: https://lirias.kuleuven.be/retrieve/15667 [Accessed 2 Mar. 2021]. |
| [16] | Fathalla, M. F. (1971). Incessant ovulation--a factor in ovarian neoplasia? Lancet (London, England), [online] 2 (7716), p. 163. Available at: https://www.ncbi.nlm.nih.gov/pubmed/4104488 [Accessed 16 Aug. 2019]. |
| [17] | Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., Znaor, A. and Bray, F. (2018). Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer. |
| [18] | Folkins, A. K., Jarboe, E. A., Saleemuddin, A., Lee, Y., Callahan, M. J., Drapkin, R., Garber, J. E., Muto, M. G., Tworoger, S. and Crum, C. P. (2008). A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecologic Oncology, 109 (2), pp. 168–173. |
| [19] | Gao, L., Wang, K., Zhou, Y., Fang, J., Qin, X. and Du, G. (2018). Uncovering the anticancer mechanism of Compound Kushen Injection against HCC by integrating quantitative analysis, network analysis and experimental validation. Scientific Reports, [online] 8 (1), p. 624. Available at: https://www.nature.com/articles/s41598-017-18325-7 [Accessed 5 Mar. 2021]. |
| [20] | Guo, Y., Huang, Y., Shen, H., Sang, X., Ma, X., Zhao, Y. and Xiao, X. (2015). Efficacy of Compound Kushen Injection in Relieving Cancer-Related Pain: A Systematic Review and Meta-Analysis. Evidence-Based Complementary and Alternative Medicine, 2015, pp. 1–8. |
| [21] | HACKER, NF (2021). Uterine cancer. [online] Practical gynecologic oncology. Available at: https://ci.nii.ac.jp/naid/10020572096/ [Accessed 2 Mar. 2021]. |
| [22] | Harada K, Scanning electron microscopic studies on the cell surface and cell synchronized culture of human endometrial adenocarcinoma (HEC-1) cells. Acta Obst Gynae Jpn, 1987; 39: 531-538Search ResultsWeb results. |
| [23] | Holinka, C. F., Hata, H., Kuramoto, H. and Gurpide, E. (1986). Responses to estradiol in a human endometrial adenocarcinoma cell line (Ishikawa). Journal of Steroid Biochemistry, [online] 24 (1), pp. 85–89. Available at: https://pubmed.ncbi.nlm.nih.gov/3702430/ [Accessed 3 Mar. 2021]. |
| [24] | Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C. and Thun, M. J. (2006). Cancer Statistics, 2006. CA: A Cancer Journal for Clinicians, 56 (2), pp. 106–130. |
| [25] | Karahan, N., Güney, M., Baspinar, S., Oral, B., Kapucuoglu, N. and Mungan, T. (2007). Expression of gelatinase (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma. European Journal of Gynaecological Oncology, [online] 28 (3), pp. 184–188. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17624083 [Accessed 5 Mar. 2021]. |
| [26] | Kitchener, H. C. and Trimble, E. L. (2009). Endometrial Cancer State of the Science Meeting. International Journal of Gynecologic Cancer, [online] 19 (1). Available at: https://ijgc.bmj.com/content/19/1/134.abstract [Accessed 5 Mar. 2021]. |
| [27] | Kuramoto, H. (1972). Studies of the growth and cytogenetic properties of human endometrial adenocarcinoma in culture and its development into an established line. Acta Obstetrica Et Gynaecologica Japonica, [online] 19 (1), pp. 47–58. Available at: https://pubmed.ncbi.nlm.nih.gov/4678779/ [Accessed 3 Mar. 2021]. |
| [28] | Kuramoto H & Suzuki K: Effects of progesterone on the growth kinetics and the morphology of a human endometrial cancer cell-line. Act Obstet Gynaec Jpn, 1976; 23: 123-32. |
| [29] | Kuramoto, H., Hamano, M. and Imai, M. (2002). HEC-1 cells. Human Cell, [online] 15 (2), pp. 81–95. Available at: http://link.springer.com/content/pdf/10.1111%2Fj.1749-0774.2002.tb00103.x.pdf [Accessed 3 Mar. 2021]. |
| [30] | Kuramoto, H., Tamura, S. and Notake, Y. (1972). Establishment of a cell line of human endometrial adenocarcinoma in vitro. American Journal of Obstetrics and Gynecology, [online] 114 (8), pp. 1012–1019. Available at: https://pubmed.ncbi.nlm.nih.gov/4673779/ [Accessed 3 Mar. 2021]. |
| [31] | Le Bars, D., Gozariu, M. and Cadden, S. W. (2001). Animal models of nociception. Pharmacological Reviews, [online] 53 (4), pp. 597–652. Available at: https://pubmed.ncbi.nlm.nih.gov/11734620/ [Accessed 2 Mar. 2021]. |
| [32] | Lee, C. (2000). Angiogenesis of endometrial carcinomas assessed by measurement of intratumoral blood flow, microvessel density, and vascular endothelial growth factor levels. Obstetrics & Gynecology, 96 (4), pp. 615–621. |
| [33] | Lee, Y., Miron, A., Drapkin, R., Nucci, M., Medeiros, F., Saleemuddin, A., Garber, J., Birch, C., Mou, H., Gordon, R., Cramer, D., McKeon, F. and Crum, C. (2006). A candidate precursor to serous carcinoma that originates in the distal fallopian tube. The Journal of Pathology, 211 (1), pp. 26–35. |
| [34] | Leitzmann, M. F., Koebnick, C., Danforth, K. N., Brinton, L. A., Moore, S. C., Hollenbeck, A. R., Schatzkin, A. and Lacey, J. V. (2009). Body mass index and risk of ovarian cancer. Cancer, 115 (4), pp. 812–822. |
| [35] | Ling, Q., Xu, X., Wei, X., Wang, W., Zhou, B., Wang, B. and Zheng, S. (2011). Oxymatrine induces human pancreatic cancer PANC-1 cells apoptosis via regulating expression of Bcl-2 and IAP families, and releasing of cytochrome c. Journal of Experimental & Clinical Cancer Research, [online] 30 (1), p. 66. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3141557/ [Accessed 3 Nov. 2019]. |
| [36] | Li ZHR: The pharmaceutical effect and clinical development of kushenin. West China J Pharm Sci 18: 435-437, 2003 Li ZHR. |
| [37] | Luoto, R., Raitanen, J., Pukkala, E. and Anttila, A. (2004). Effect of hysterectomy on incidence trends of endometrial and cervical cancer in Finland 1953–2010. British Journal of Cancer, [online] 90 (9), pp. 1756–1759. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409756/ [Accessed 2 Mar. 2021]. |
| [38] | LYONS, R. M. and MOSES, H. L. (1990). Transforming growth factors and the regulation of cell proliferation. European Journal of Biochemistry, 187 (3), pp. 467–473. |
| [39] | Madison, T., Schottenfeld, D., James, S. A., Schwartz, A. G. and Gruber, S. B. (2004). Endometrial Cancer: Socioeconomic Status and Racial/Ethnic Differences in Stage at Diagnosis, Treatment, and Survival. American Journal of Public Health, 94 (12), pp. 2104–2111. |
| [40] | Malcangio, M. and Bowery, N. G. (1996). GABA and its receptors in the spinal cord. Trends in Pharmacological Sciences, [online] 17 (12), pp. 457–462. Available at: https://pubmed.ncbi.nlm.nih.gov/9014500/ [Accessed 2 Mar. 2021]. |
| [41] | Malhotra, J., Jabbour, S. K. and Aisner, J. (2017). Erratum to current state of immunotherapy for non-small cell lung cancer. Translational Lung Cancer Research, 6 (5), pp. 612–612. |
| [42] | Ma, X., Li, R.-S., Wang, J., Huang, Y.-Q., Li, P.-Y., Wang, J., Su, H.-B., Wang, R.-L., Zhang, Y.-M., Liu, H.-H., Zhang, C.-E., Ma, Z.-J., Wang, J.-B., Zhao, Y.-L. and Xiao, X.-H. (2016). The Therapeutic Efficacy and Safety of Compound Kushen Injection Combined with Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma: An Update Systematic Review and Meta-Analysis. Frontiers in Pharmacology, [online] 7, p. 70. Available at: https://pubmed.ncbi.nlm.nih.gov/27065861/ [Accessed 5 Mar. 2021]. |
| [43] | McPherson, C. P., Sellers, T. A., Potter, J. D., Bostick, R. M. and Folsom, A. R. (1996). Reproductive factors and risk of endometrial cancer. The Iowa Women’s Health Study. American Journal of Epidemiology, [online] 143 (12), pp. 1195–1202. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8651218/ [Accessed 2 Mar. 2021]. |
| [44] | Millan, M. J. (2002). Descending control of pain. Progress in Neurobiology, 66 (6), pp. 355–474. |
| [45] | Moses, H. L., Yang, E. Y. and Pietenpol, J. A. (1990). TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell, [online] 63 (2), pp. 245–247. Available at: https://pubmed.ncbi.nlm.nih.gov/2208284/ [Accessed 4 Mar. 2021]. |
| [46] | Nishida, M., Kasahara, K., Kaneko, M., Iwasaki, H. and Hayashi, K. (1985). [Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors]. Nihon Sanka Fujinka Gakkai Zasshi, [online] 37 (7), pp. 1103–1111. Available at: https://pubmed.ncbi.nlm.nih.gov/4031568/ [Accessed 3 Mar. 2021]. |
| [47] | Noumoff J, Haydock SW, Sachdeva R, Heyner S & Prichard ML: Characteristics of cell lines derived from normal and malignant endometrium. Gynecol Oncol, 1987; 27: 141-149. |
| [48] | Olaso, E. and Vidal-Vanaclocha, F. (2003). Use of tumor-activated hepatic stellate cell as a target for the preclinical testing of anti-angiogenic drugs against hepatic tumor development. Methods in Molecular Medicine, [online] 85, pp. 79–86. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12710199 [Accessed 5 Mar. 2021]. |
| [49] | Parkin, D. M., Pisani, P. and Ferlay, J. (1999). Global cancer statistics. CA: A Cancer Journal for Clinicians, 49 (1), pp. 33–64. |
| [50] | Prensner, J. R., Iyer, M. K., Balbin, O. A., Dhanasekaran, S. M., Cao, Q., Brenner, J. C., Laxman, B., Asangani, I., Grasso, C., Kominsky, H. D., Cao, X., Jing, X., Wang, X., Siddiqui, J., Wei, J. T., Robinson, D., Iyer, H. K., Palanisamy, N., Maher, C. A. and Chinnaiyan, A. M. (2011). Transcriptome Sequencing Identifies PCAT-1, a Novel lincRNA Implicated in Prostate Cancer Progression. Nature biotechnology, [online] 29 (8), pp. 742–749. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152676/ [Accessed 10 Feb. 2021]. |
| [51] | Qu, Z., Cui, J., Harata-Lee, Y., Aung, T. N., Feng, Q., Raison, J. M., Kortschak, R. D. and Adelson, D. L. (2016). Identification of candidate anti-cancer molecular mechanisms of Compound Kushen Injection using functional genomics. Oncotarget, [online] 7 (40), pp. 66003–66019. Available at: https://www.oncotarget.com/article/11788/text/ [Accessed 5 Mar. 2021]. |
| [52] | Rodrigues, A. L. S., da Silva, G. L., Mateussi, A. S., Fernandes, E. S., Miguel, O. G., Yunes, R. A., Calixto, J. B. and Santos, A. R. S. (2002). Involvement of monoaminergic system in the antidepressant-like effect of the hydroalcoholic extract of Siphocampylus verticillatus. Life Sciences, 70 (12), pp. 1347–1358. |
| [53] | Satyaswaroop, P. G., Fleming, H., Bressler, R. S. and Gurpide, E. (1978). Human Endometrial Cancer Cell Cultures for Hormonal Studies. Cancer Research, [online] 38 (11 Part 2), pp. 4367–4375. Available at: https://cancerres.aacrjournals.org/content/38/11_Part_2/4367.short [Accessed 4 Mar. 2021]. |
| [54] | SCHILDKRAUT, J. (1996). Epithelial Ovarian Cancer Risk Among Women With Polycystic Ovary Syndrome. Obstetrics & Gynecology, 88 (4), pp. 554–559. |
| [55] | Schildkraut, J. M., Bastos, E. and Berchuck, A. (1997). Relationship Between Lifetime Ovulatory Cycles and Overexpression of Mutant p53 in 932 Epithelial Ovarian Cancer. JNCI Journal of the National Cancer Institute, 89 (13), pp. 932–938. |
| [56] | Schouten, L. J., Goldbohm, R. A. and van den Brandt, P. A. (2004). Anthropometry, Physical Activity, and Endometrial Cancer Risk: Results from The Netherlands Cohort Study. JNCI Journal of the National Cancer Institute, 96 (21), pp. 1635–1638. |
| [57] | Schouten, L. J., Rivera, C., Hunter, D. J., Spiegelman, D., Adami, H. O., Arslan, A., Beeson, W. L., Brandt, P. A. van den, Buring, J. E., Folsom, A. R., Fraser, G. E., Freudenheim, J. L., Goldbohm, R. A., Hankinson, S. E., Lacey, J. V., Leitzmann, M., Lukanova, A., Marshall, J. R., Miller, A. B. and Patel, A. V. (2008). Height, Body Mass Index, and Ovarian Cancer: A Pooled Analysis of 12 Cohort Studies. Cancer Epidemiology and Prevention Biomarkers, [online] 17 (4), pp. 902–912. Available at: https://cebp.aacrjournals.org/content/17/4/902.short [Accessed 5 Feb. 2021]. |
| [58] | SEER. (2005). SEER Cancer Statistics Review 1975-2005 - Previous Version - SEER Cancer Statistics. [online] Available at: http://seer.cancer.gov/csr/1975_2005/ [Accessed 2 Mar. 2021]. |
| [59] | SEER. (2018). Surveillance, Epidemiology, and End Results Program. [online] Available at: https://seer.cancer.gov/. |
| [60] | Sekiya, S. and Takamizawa, H. (1981). [Effect of anticancer drugs on in vitro survival of cell lines derived from various gynecologic tumors (author’s transl)]. Acta Obstetrica Et Gynaecologica Japonica, [online] 33 (3), pp. 373–376. Available at: https://pubmed.ncbi.nlm.nih.gov/6163305/ [Accessed 3 Mar. 2021]. |
| [61] | Smith, R. A., Cokkinides, V. and Eyre, H. J. (2003). American Cancer Society Guidelines for the Early Detection of Cancer, 2003. CA: A Cancer Journal for Clinicians, 53 (1), pp. 27–43. |
| [62] | Sporn, M. B. and Roberts, A. B. (1990). TGF-beta: problems and prospects. Cell Regulation, 1 (12), pp. 875–882. |
| [63] | Stoscheck, C. M. and King, L. E. (1986). Role of epidermal growth factor in carcinogenesis. Cancer Research, [online] 46 (3), pp. 1030–1037. Available at: https://pubmed.ncbi.nlm.nih.gov/3002608/ [Accessed 4 Mar. 2021]. |
| [64] | Sun, M., Cao, H., Sun, L., Dong, S., Bian, Y., Han, J., Zhang, L., Ren, S., Hu, Y., Liu, C., Xu, L. and Liu, P. (2012). Antitumor Activities of Kushen: Literature Review. [online] Evidence-Based Complementary and Alternative Medicine. Available at: https://www.hindawi.com/journals/ecam/2012/373219/ [Accessed 8 Mar. 2021]. |
| [65] | Thomsen, M., Wörtwein, G., Olesen, M. V., Begtrup, M., Havez, S., Bolwig, T. G. and Woldbye, D. P. D. (2007). Involvement of Y (5) receptors in neuropeptide Y agonist-induced analgesic-like effect in the rat hot plate test. Brain Research, [online] 1155, pp. 49–55. Available at: https://pubmed.ncbi.nlm.nih.gov/17498669/ [Accessed 2 Mar. 2021]. |
| [66] | Tianyou Liu, Song, Y., Hua Chen, Shangha Pan and Sun, X. (2019). Matrine inhibits proliferation and induces apoptosis of pancreatic cancer cells in vitro and in vivo. [online] Unboundmedicine.com. Available at: https://www.ncbi.nih.ncbi.unboundmedicine.com/medline/citation/20930385/Matrine_inhibits_proliferation_and_induces_apoptosis_of_pancreatic_cancer_cells_in_vitro_and_in_vivo_ [Accessed 5 Mar. 2021]. |
| [67] | TRENTIN, A. P., SANTOS, A. R. S., MIGUEL, O. G., PIZZOLATTI, M. G., YUNES, R. A. and CALIXTO, Jo. B. (1997). Mechanisms Involved in the Antinociceptive Effect in Mice of the Hydroalcoholic Extract of Siphocampylus verticillatus. Journal of Pharmacy and Pharmacology, 49 (5), pp. 567–572. |
| [68] | Tu, H., Lei, B., Meng, S., Liu, H., Wei, Y., He, A., Zhang, W. and Zhou, F. (2016). Efficacy of Compound Kushen Injection in Combination with Induction Chemotherapy for Treating Adult Patients Newly Diagnosed with Acute Leukemia. Evidence-based Complementary and Alternative Medicine: eCAM, [online] 2016. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5050378/ [Accessed 5 Mar. 2021]. |
| [69] | Wang, H., Hu, H., Rong, H. and Zhao, X. (2019). Effects of compound Kushen injection on pathology and angiogenesis of tumor tissues. Oncology Letters, [online] 17 (2), pp. 2278–2282. Available at: https://www.spandidos-publications.com/ol/17/2/2278# [Accessed 5 Mar. 2021]. |
| [70] | Wang, L., Zhou, G.-B., Liu, P., Song, J.-H., Liang, Y., Yan, X.-J., Xu, F., Wang, B.-S., Mao, J.-H., Shen, Z.-X., Chen, S.-J. and Chen, Z. (2008). Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, [online] 105 (12), pp. 4826–4831. Available at: https://pubmed.ncbi.nlm.nih.gov/18344322/ [Accessed 5 Mar. 2021]. |
| [71] | Wang, W., You, R., Qin, W., Hai, L., Fang, M., Huang, G., Kang, R., Li, M., Qiao, Y., Li, J. and Li, A. (2015). Anti-tumor activities of active ingredients in Compound Kushen Injection. Acta Pharmacologica Sinica, [online] 36 (6), pp. 676–679. Available at: https://pubmed.ncbi.nlm.nih.gov/25982630/. |
| [72] | Wang XH, Huang SK and Lin P: Pharmacokinetics and pharmacodynamics of sophocarpine and oxysophocarpine. J China Pharm Univ 23: 161-164, 1992. |
| [73] | Wang, X., Liu, J., Lin, H. and Hou, W. (2016). A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomized controlled trial. Trials, 17 (1). |
| [74] | Weigel, M. T., Krämer, J., Schem, C., Wenners, A., Alkatout, I., Jonat, W., Maass, N. and Mundhenke, C. (2012). Differential expression of MMP-2, MMP-9 and PCNA in endometriosis and endometrial carcinoma. European Journal of Obstetrics & Gynecology and Reproductive Biology, [online] 160 (1), pp. 74–78. Available at: https://www.sciencedirect.com/science/article/pii/S0301211511005598 [Accessed 5 Mar. 2021]. |
| [75] | White, N. M., Cabanski, C. R., Silva-Fisher, J. M., Dang, H. X., Govindan, R. and Maher, C. A. (2014). Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer. Genome Biology, 15 (8). |
| [76] | Wild, S., Pierpoint, T., Jacobs, H. and McKeigue, P. (2000). Long-term consequences of polycystic ovary syndrome: Results of a 31 year follow-up study. Human Fertility, 3 (2), pp. 101–105. |
| [77] | www.cancer.org. (2008). Cancer Facts & Figures 2008 | American Cancer Society. [online] Available at: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2008.html#:~:text=About%201%2C437%2C180%20new%20cancer%20cases [Accessed 2 Mar. 2021]. |
| [78] | XU, T., LI, Y., WANG, H., XU, Y., MA, L., SUN, T., MA, H. and YU, J. (2013). Oxysophocarpine induces anti-nociception and increases the expression of GABAAα1 receptors in mice. Molecular Medicine Reports, 7 (6), pp. 1819–1825. |
| [79] | Xu, W., Lin, H., Zhang, Y., Chen, X., Hua, B., Hou, W., Qi, X., Pei, Y., Zhu, X., Zhao, Z. and Yang, L. (2011). Compound Kushen Injection suppresses human breast cancer stem-like cells by down-regulating the canonical Wnt/β-catenin pathway. Journal of Experimental & Clinical Cancer Research: CR, [online] 30 (1), p. 103. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219673/ [Accessed 5 Mar. 2021]. |
| [80] | Yong-gang, C., Shan, J., Lei, L., Jing-quan, G., Zhi-ying, S., Yan, L., Yan, X., Ming-li, W., Ye, W., Chang-qing, X. and Hong-li, S. (2010). Antiarrhythmic effects and ionic mechanisms of oxymatrine from Sophora flavescens. Phytotherapy Research, 24 (12), pp. 1844–1849. |
| [81] | Young, R. H. and Clement, P. B. (2002). Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis. Histopathology, 41 (3), pp. 185–207. |
| [82] | Yu, L., Zhou, Y., Yang, Y., Lu, F. and Fan, Y. (2017). Efficacy and Safety of Compound Kushen Injection on Patients with Advanced Colon Cancer: A Meta-Analysis of Randomized Controlled Trials. [online] Evidence-Based Complementary and Alternative Medicine. Available at: https://www.hindawi.com/journals/ecam/2017/7102514/ [Accessed 5 Mar. 2021]. |
| [83] | Yu, P., Liu, Q., Liu, K., Yagasaki, K., Wu, E. and Zhang, G. (2009). Matrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-κB signaling. Cytotechnology, 59 (3), pp. 219–229. |
| [84] | Zaino, R. J., Kurman, R. J., Brunetto, V. L., Morrow, C. P., Bentley, R. C., Cappellari, J. O. and Bitterman, P. (1998). Villoglandular adenocarcinoma of the endometrium: a clinicopathologic study of 61 cases: a gynecologic oncology group study. The American Journal of Surgical Pathology, [online] 22 (11), pp. 1379–1385. Available at: https://pubmed.ncbi.nlm.nih.gov/9808130/ [Accessed 2 Mar. 2021]. |
| [85] | Zhang, Y., Hui, F., Yang, Y., Chu, H., Qin, X., Zhao, M. and Zhao, Q. (2017). Can Kushen injection combined with TACE improve therapeutic efficacy and safety in patients with advanced HCC? a systematic review and network meta-analysis. Oncotarget, [online] 8 (63), pp. 107258–107272. Available at: https://www.oncotarget.com/article/20921/text/ [Accessed 5 Mar. 2021]. |
| [86] | Zhao, Z., Fan, H., Higgins, T., Qi, J., Haines, D., Trivett, A., Oppenheim, J. J., Wei, H., Li, J., Lin, H. and Howard, O. M. Z. (2014). Fufang Kushen injection inhibits sarcoma growth and tumor-induced hyperalgesia via TRPV1 signaling pathways. Cancer Letters, [online] 355 (2), pp. 232–241. Available at: https://pubmed.ncbi.nlm.nih.gov/25242356/ [Accessed 5 Mar. 2021]. |
| [87] | Zhao, Z., Liao, H. and Ju, Y. (2016). Effect of compound Kushen injection on T-cell subgroups and natural killer cells in patients with locally advanced non-small-cell lung cancer treated with concomitant radiochemotherapy. Journal of Traditional Chinese Medicine = Chung I Tsa Chih Ying Wen Pan, [online] 36 (1), pp. 14–18. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26946613 [Accessed 5 Mar. 2021]. |
APA Style
Sadik Yusuf Musse. (2022). Effect of Oxysophocarpine on Proliferation and Invasion of Endometrial Cancer HEC-1-B Cells and Related Proteins. Journal of Gynecology and Obstetrics, 10(2), 97-107. https://doi.org/10.11648/j.jgo.20221002.17
ACS Style
Sadik Yusuf Musse. Effect of Oxysophocarpine on Proliferation and Invasion of Endometrial Cancer HEC-1-B Cells and Related Proteins. J. Gynecol. Obstet. 2022, 10(2), 97-107. doi: 10.11648/j.jgo.20221002.17
AMA Style
Sadik Yusuf Musse. Effect of Oxysophocarpine on Proliferation and Invasion of Endometrial Cancer HEC-1-B Cells and Related Proteins. J Gynecol Obstet. 2022;10(2):97-107. doi: 10.11648/j.jgo.20221002.17
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.jgo.20221002.17,
author = {Sadik Yusuf Musse},
title = {Effect of Oxysophocarpine on Proliferation and Invasion of Endometrial Cancer HEC-1-B Cells and Related Proteins},
journal = {Journal of Gynecology and Obstetrics},
volume = {10},
number = {2},
pages = {97-107},
doi = {10.11648/j.jgo.20221002.17},
url = {https://doi.org/10.11648/j.jgo.20221002.17},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jgo.20221002.17},
abstract = {Endometrial cancer is one of the most common cancer of the female reproductive tract, which has been one of the primary causes of cancer related deaths and accounts for approximately ¼ of these patients. In this paper, HEC-1 cell l i n e s that are known to propagate endometrial cancer have been considered as potential sites of action for various therapeutic agents in an attempt to combat proliferation. Ancient Chinese remedies are by far the most recognized therapeutic method which have been found to relieve patients suffering from a tumor and also suppresses tumor growth. This study researches the effect of an injection formulation of the compound Kushen, which is a large oxysophocarpine-associated compound. In CKI- handled tumor cells, cellular proliferation through DNA synthesis and mobile differentiation seems to be a surprisingly modified mechanism. Cell cycle inhibition is seen to be one of the key mechanisms in CKI mediated tumor suppression in most instances. This is based on the fact that aggregates display certain 2-D specifications and dimerization of genes within the proposed mechanisms [10]. There is, nevertheless, little to no proof that oxysophocarpine, specifically in endometrial cells HEC-1B, inhibits the growth of most cancers’ cells.},
year = {2022}
}
TY - JOUR T1 - Effect of Oxysophocarpine on Proliferation and Invasion of Endometrial Cancer HEC-1-B Cells and Related Proteins AU - Sadik Yusuf Musse Y1 - 2022/03/23 PY - 2022 N1 - https://doi.org/10.11648/j.jgo.20221002.17 DO - 10.11648/j.jgo.20221002.17 T2 - Journal of Gynecology and Obstetrics JF - Journal of Gynecology and Obstetrics JO - Journal of Gynecology and Obstetrics SP - 97 EP - 107 PB - Science Publishing Group SN - 2376-7820 UR - https://doi.org/10.11648/j.jgo.20221002.17 AB - Endometrial cancer is one of the most common cancer of the female reproductive tract, which has been one of the primary causes of cancer related deaths and accounts for approximately ¼ of these patients. In this paper, HEC-1 cell l i n e s that are known to propagate endometrial cancer have been considered as potential sites of action for various therapeutic agents in an attempt to combat proliferation. Ancient Chinese remedies are by far the most recognized therapeutic method which have been found to relieve patients suffering from a tumor and also suppresses tumor growth. This study researches the effect of an injection formulation of the compound Kushen, which is a large oxysophocarpine-associated compound. In CKI- handled tumor cells, cellular proliferation through DNA synthesis and mobile differentiation seems to be a surprisingly modified mechanism. Cell cycle inhibition is seen to be one of the key mechanisms in CKI mediated tumor suppression in most instances. This is based on the fact that aggregates display certain 2-D specifications and dimerization of genes within the proposed mechanisms [10]. There is, nevertheless, little to no proof that oxysophocarpine, specifically in endometrial cells HEC-1B, inhibits the growth of most cancers’ cells. VL - 10 IS - 2 ER -
Information
Email: